Actively Recruiting
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-03
184
Participants Needed
1
Research Sites
177 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy.
CONDITIONS
Official Title
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Diagnosed with AML (non-M3) according to WHO 2016 standards
- No previous treatment for AML
- Not eligible for intensive chemotherapy due to age (75 years or older) or age 18 to 74 with specific comorbidities such as ECOG performance status 2 or 3, certain heart diseases, lung function limitations, kidney function between 30 to less than 45 mL/min clearance, moderate liver impairment, or other comorbidities judged by physician
- ECOG performance status 0 to 2 if aged 75 or older, or 0 to 3 if aged 18 to 74
- Expected survival time of 3 months or more
- Ability to understand and willing to sign informed consent
You will not qualify if you...
- Having other malignant tumors
- Previous treatment with chidamide, venetoclax, or azacitidine
- Low-risk AML per NCCN 2022 guidelines with specific genetic markers
- AML infiltration in the central nervous system
- Cardiac angioplasty or stent placement within 12 months, history of myocardial infarction, unstable angina, or significant heart disease
- Active infections or uncontrolled organ bleeding
- Pregnant or lactating women
- Participation in other clinical trials within 3 months prior to consent
- Any condition deemed unsuitable for study participation by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Blood Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
J
Jianxiang Wang, Medical PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here